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The term  interleukin  1 (IL-1) encompasses macrophage-derived polypeptide 
factors in  man,  mouse, and  other animals,  which  stimulate  murine  thymocyte 
proliferation  (1-3),  and  in  addition  activate  various  target  cells  involved  in 
chronic  inflammation  (4-10).  The  IL-1  produced  by the  murine  macrophage 
line,  P388D1, has a  low isoelectric point (pI) and exhibits micro-charge  hetero- 
geneity in  the  range  of 4.9-5.2  (11).  P388Dl-derived  IL-1  has  been  purified 
(1 1), and a complementary DNA (cDNA) 1 coding for the precursor form of this 
molecule has been recently cloned (12). The nucleic acid sequence of this cDNA 
was validated by sequencing peptides of P388Dl-derived I L-1 protein (12). 
The  study  of human  IL-1  has  lagged  behind  that  of murine  IL-1  largely 
because of the unavailability of a tumor line capable of making large amounts of 
IL-1. In addition,  human  IL-1 appears more complex than murine IL-1, in that 
there are several major charged species (4, 5,  13). Like murine IL-1, two of these 
species have low pI, 5. ! and 5.3.  Porcine IL-1, also known as catabolin, also has 
a pI in this range (14). In contrast to the mouse and pig, there is, in man, a third 
type, with a pI of 6.0, and a fourth, dominant species, with a pI of 6.8 (4, 5,  13). 
The  pI  6.8  species has been purified  (15),  while several of the  low-pI human 
types have been purified  by others (16).  The biochemical relationships  among 
these various charged species is not known, though their similar bioactivities on 
fibroblasts (4,  5) and  other  target  cells (17) have suggested to some that  they 
might share similar core structures. 
A  cDNA  putatively  coding  for  a  human  IL-1  molecule  has  recently  been 
reported (18).  The  translation  product derived from this cDNA was (a) active 
on  D10.G4.1  T  cells, a  cell  line responsive to partially purified preparations  of 
murine  IL-1  (19),  and  (b) precipitated  by a  polyspecific antiserum  containing 
antibodies against several charged species of human  IL-1 (20), and several other 
macrophage-derived  products  (18).  However, the  translation  product  was not 
shown  to  be active  in  the  murine  thymocyte proliferation  assay,  the  standard 
assay for all  IL-1  molecules.  Furthermore,  no amino acid sequence analysis of 
l Abbreviations used in this paper:  cDNA. complementary DNA; HPLC, high-performance liquid 
chromatography; 1L-I, interleukin 1; PITC, phenyl isothiocyanate;  PTH, phenylthiohydantoin; SDS- 
PAGE, sodium dodecyl  sulfate-polyacrylamide  gel electrophoresis; TFA, trifluoroacetic acid. 
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purified IL-1 was presented to confirm that the cDNA coded for one or several 
of the human IL-1 species described previously. Interestingly, comparison of the 
deduced  amino  acid  sequences  of the  murine  and  human  cDNA  reveals  little 
homology. This observation raises the possibility, despite the similar spectrum of 
bioactivities  exhibited  by murine  and  human  IL-I, that  there  are  several  bio- 
chemically distinct  types of IL-1  or,  alternatively, that  the  human cDNA clone 
represents a novel class of mediator, discovered by molecular genetic techniques, 
which is largely distinct from the class of mediators known as IL-1. 
In this report,  the  primary amino acid sequences of the amino terminus and 
three CNBr cleavage fragments of the pI 6.8 species of normal human IL-1 are 
presented. The data demonstrate conclusively that the recently reported human 
cDNA codes for the pI 6.8 species of human IL-1. In addition, the identification 
of  the  amino  terminus  of  human  IL-1  reveals  that  processing  of  the  IL-I 
precursor protein  occurs at the amino terminal  portion  of the  molecule, not at 
the  carboxyl  terminus,  as  was originally  suspected  (18).  Most  importantly,  the 
data  show  that,  despite  the  strong  functional  similarities  of all  IL-1  molecules, 
there are biochemically distinct forms of IL-1. 
Materials and  Methods 
Culture Supernatant Preparation.  Normal human mononuclear cells were cultured under 
serum-free conditions, as previously described (15), with the exception that the cells were 
stimulated  with  both  phytohemagglutinin  (5  #g/ml)  and  lipopolysaccharide (1  #g/ml) 
for 96 h. The crude culture supernatants were concentrated by ultrafiltration as previously 
described (15). 
Purification of IL-1.  The pI 6.8 species of normal human IL-1 was purified from crude 
concentrated culture supernatants using a modification of a technique previously described 
(15).  The crude concentrated supernatant was dialyzed against buffer A  (20 mM Tris 
acetate,  pH  8.3),  and  loaded  on  a  high-performance  liquid  chromatography (HPLC) 
DEAE column (Bio-Gel TSK-DEAE-5-PW [21.5  X  150  mm];  Bio-Rad,  Richmond, CA) 
that was equilibrated in the same buffer. The flow rate was 4  ml/min. After 40 min, a 
linear descending pH gradient of from 0 to 50% buffer B (20 mM Tris acetate, pH 6.8) 
was initiated at a rate of 0.5% per minute. The IL-1 bioactivity typically eluted as a sharp 
peak between  138  and  142  min  from the time of injection.  The active fractions were 
pooled, concentrated by ultrafiltration  using a  YM  10  membrane (Amicon, Lexington, 
MA) to a volume of 1 ml, and loaded on a Vydac C4 reverse-phase HPLC column (0.4 x 
5 cm; Separations Group, Hesperia, CA) equilibrated in 0.1% trifluoroacetic acid (TFA). 
The flow rate was 1 ml/min. A linear gradient of 0.1% TFA in acetonitrile (0-50%) was 
used to elute the column. The absorbance of the column effluent was monitored at 210 
nm. Fractions were collected by a Pharmacia Frac-100 fraction collector equipped with a 
programmable peak-collection device. 
CNBr Cleavage oflL-1.  IL-1 (0.2 nmol), purified by reverse-phase HPLC, was treated 
with  a  3,000-fold  molar excess  of CNBr  for  72  h  at  room  temperature.  Preliminary 
experiments  showed  that  efficient  cleavage of test  proteins  could  be  obtained  in  the 
presence of 0.1% TFA and 40% acetonitrile. Nevertheless, the amount of CNBr required 
for complete cleavage of IL-1  was  100-1000-fold in excess of published protocols (21). 
Further experiments with test proteins suggested that the concentration of CNBr required 
was indirectly proportional to the concentration of the protein reactant, and that conven- 
tional protocols, which typically use milligram amounts of protein, significantly underes- 
timate the concentration of CNBr necessary to cleave low (microgram) amounts of protein. 
Peptides of IL-1 were purified by passage of the CNBr reaction mixture over a Vydac C4 
reverse-phase column using the buffer and gradient conditions mentioned above. Peptides 
were  collected  as  individual  peaks  using  the  peak  collection  feature  of the  Frac-100 792  AMINO ACID SEQUENCE OF  HUMAN INTERLEUKIN  1 
fraction collector. The absorbance of the effluent was monitored at 210 nm and 280 nm 
simultaneously by a Hewtett-Packard 1040A scanning spectrophotometric detector. 
Amino Acid Analysis.  Amino acid analysis was used to determine the concentration of 
purified  IL-1  protein.  Triplicate  samples  (25-50  pmoles)  were  taken  to  dryness  in 
borosilicate tubes  in  a  Pico-tag work  station (Waters  Associates,  Bedford,  MA).  The 
samples  were  redried  twice with  50-ttl aliquots of water,  and  then  hydrolyzed under 
nitrogen with gaseous HCl for 20  h  at  105°C.  The  hydrolysate was derivatized with 
phenylisothiocyanate (PITC) as previously described (22), to form the phenylthiocarba- 
myl-amino acid derivatives. These were separated by reverse-phase HPLC as previously 
described (22),  using a  C18  microbondapak (Waters Associates) reverse-phase column. 
The peaks were identified and quantitated by chromatography and integration of standard 
amino acid mixtures (Pierce, Rockford, IL), which were derivatized with PITC in identical 
fashion. SEM for each of the 17 assayable amino acids was always <10% of the mean, and 
usually <5%  of the mean.  Values  obtained for tyrosine, isoleucine, and leucine were 
particularly reproducible, and were used for mass determinations using values of 4,  5, 
and 15 moles, respectively, per mole IL-1 (18,000 mol wt). 
Sequence Analysis.  IL-1  and  IL-1  peptides  were  applied  in  several  applications  to 
polybrene-coated filters and sequenced using an automated gas-phase sequencer employ- 
ing Edman chemistry (model 470A;  Applied Biosystems,  Foster City, CA).  The ATZ 
amino acids  were treated in  the conversion flask with HCI and methanol to form the 
methyl esters of the phenylthiohydantoin (PTH) derivatives of glutamic acid and aspartic 
acid. The PTH amino acids were identified by reverse-phase HPLC, and quantitated by 
integration as previously described (23). 
Homology Analysis.  The search for homologous regions between the murine and pu- 
tative human IL-1  cDNA and their respective deduced amino acid sequences was aided 
by computer analysis on a Digital VAX-11/780 computer, using the Needleman-Wunsch 
homology search algorithm (24) (Intelligenetics, Palo Alto, CA). 
Biological Assay oflL-1.  IL-1  was assayed in the murine thymocyte proliferation assay 
as previously described (15). Samples were assayed in parallel with aliquots of a partially 
purified preparations of IL-1, which consistently gave 550 half-maximal U/ml. Compari- 
son of the sample and standard preparations at a level of 50% of maximal stimulation was 
performed as previously described (15). 
Results 
The human IL-1  used for sequence analysis was purified by a modification of 
a  protocol  described  previously (15).  The  modified protocol  also  used anion- 
exchange HPLC, but employed a  resin-based,  pH-stable column (see  Materials 
and  Methods),  which made it possible  to  load at higher pH  (8.3)  and achieve 
tight binding of the pI 6.8 species of human IL-1. The column was then eluted 
with a descending pH gradient (pH 8.3-6.8), which provided excellent resolution 
of IL-1 from nearby contaminants (data not shown). The active fractions obtained 
from the ion-exchange HPLC column were  further purified by reverse-phase 
HPLC. A  sharp,  dominant peak corresponding with IL-1 activity was observed 
(Fig.  1). This material was similar to that isolated by the previous protocol (15), 
in that it gave a  single band having a  pI of 6.8 by analytical isoelectrofocusing 
(data  not  shown).  Furthermore,  when  analyzed  by  sodium  dodecyl  sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) in 15% homogeneous gels under 
reducing conditions, a single silver-staining band of mol wt 18,000 was observed 
(data  not  shown).  The  material  that  was  previously isolated  had  a  molecular 
weight  of  15,000  using  10-30%  gradient  SDS-PAGE.  IL-1  purified  by  the 
previous protocol was found to have a specific bioactivity of 6 X 106 half-maximal 
U/mg in the murine thymocyte proliferation assay, using absorbance at 210 nm t-- 
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FIGURE  l.  Reverse-phase HPLC of human IL-1. Serum-free mononuclear cell supernatants 
were concentrated and partially purified by anion-exchange HPLC, as described in Materials 
and Methods. The active fractions were pooled, concentrated, and loaded onto a  Vydac C4 
reverse-phase HPLC column equilibrated in 0.1% TFA in water. The column was eluted with 
a linear gradient of 0.1% TFA in acetonitrile (0-50%) at a rate of 2% per minute. The colunm 
effluent was monitored at  210  nm (top).  Fractions were collected using the peak collection 
feature of a  programmable fraction collector, and assayed for IL-1  activity in  the murine 
thymocyte proliferation assay (bottom). 
as a measure of protein concentration. Material purified by the current protocol 
gave  1.7 ×  107  U/mg, using amino acid analysis as a  more accurate measure of 
protein concentration. 
Amino-terminal  sequence analysis was performed on  150 pmoles of purified 
IL-1,  as  described  in  Materials  and  Methods.  A  single  amino  terminus  was 794  AMINO  ACID  SEQUENCE  OF  HUMAN  INTERLEUKIN  1 
5  10 
ALA-PRO-VAL-ARG-SER-LEU-ASN-  X  -THR-LEU- 
15  20 
ARG-ASP-SER-GLN-GLN-LYS-SER- LEU-VAL-M ET- 
25  3O 
SER-GLY-PRO-TYR-GLU-LEU-LYS-ALA-LEU-  X  - 
35 
X  -GLN-  X  -  X  -ASP 
FIGURE 2.  Anfino-terminal sequence analysis of human IL-1.  150 pmoles of reverse-phase- 
purified IL-I  were sequenced by an automated gas-phase sequencer using Edman chemistry. 
The PTH-derivatives of each residue were identified by reverse-phase HPLC as detailed in 
Materials and Methods. X designates residues that could not be clearly identified. 
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FIGURE  3.  Reverse-phase HPLC of CNBr cleavage fragments of human IL-1. Human IL-1 
was treated with an excess of CNBr (see Materials and Methods), and the resulting peptides 
were separated by reverse-phase HPLC and collected as described in the legend to Fig. 1. The 
column effluent was  monitored at  210  nm  (0.05  absorbance units, full scale) and  280  nm 
(0.005 absorbance units, full scale) simultaneously. The peaks identified as I, II, and Ill were 
subsequently sequenced. 
observed (Fig. 2). Analysis of another preparation of purified material revealed 
the same, single amino terminus. The yield, as determined by quantitation of 
the second PTH-amino acid derivative, was 65%. This value was similar to that 
obtained (25)  when highly purified sperm  whale myoglobin was  similarly ana- 
lyzed, and suggests that our preparation was not contaminated by proteins having 
blocked amino termini. 30 of the first 35 N-terminal amino acids were unambig- 
uously identified in  the  two  analyses.  The  seventh  residue  in  the  sequence, 
asparagine, was a potential site for N-glycosylation (18), but chromatograpbed as 
the free PTH derivative during reverse-phase HPLC. 
To obtain  internal amino acid sequence,  200  pmoles of purified IL-1  were 
cleaved  with  CNBr,  as  described  in  Materials  and  Methods.  The  resulting 
peptides were purified and isolated by reverse-phase HPLC (Fig. 3). As expected, CAMERON  ET  AL.  795 
CNIr  Peptide I 
SER-GLY-PRO-TYR-GLU-LEU-LYS-ALA-LEU- X  - 
LEU-GLN-GLY-  X  -ASP-  X 
CNBr  Peptlde II 
PRO-VAL-PHF-LEU-GLY-GLY-THR-LYS-GLY-GLY- 
GLN-ASP-I LF-THR-ASP-PHE-THR-  X 
CNBr  Peptlde Ill 
GLU-LYS-ARG-PHE-VAL-PHE-ASN-LYS- I LE-GLU-ILE- 
ASN-ASN-LYS-LEU-GLU-PHE-GLU-  X  -ALA-  X 
FIGURE 4.  Amino acid  sequences of three  CNBr  peptides of human  IL-I.  X  designates 
residues that could not be clearly identified. 
the aromatic content of the peptides was variable, as indicated by their differential 
absorbance at 280 nm. The indicated peaks (I, II, and III in Fig. 3) were peak- 
collected and sequenced, as above. The results are shown in Fig. 4.  13 of 16, 17 
of 18, and 19 of 21 amino acid residues were identified in peptides I, II, and III, 
respectively. 
The amino acid sequences presented in Figs. 2 and 4 correspond exactly with 
the amino acid sequence deduced from a  cloned cDNA  by Auron, et al.  (18). 
Those portions of the deduced sequence that have been confirmed by protein 
sequence data are capitalized in Fig. 5. Also shown is the alignment of the human 
translation  product with the translation  product deduced from the cDNA for 
murine IL-1  (12). The alignment includes gaps suggested by computer analysis 
using the Needleman-Wunsch homology algorithm (see Materials and Methods). 
Only 30% (80 of 270) homology is observed overall. Comparison of the secreted 
portions of the translation products shows only 29%  (45 of 155) homology. In 
contrast, comparison of the N-terminal sequence of human I L-1 with the recently 
reported N-terminal sequence of interferon-inducing factor (26) reveals 63% (24 
of 38)  homology. Comparison of the nucleotide sequences of the murine and 
human IL-1 cDNA using the same homology algorithm revealed 43% homology 
(data not shown). 
Discussion 
We have isolated the major charged species of normal human IL-1, using an 
improved  version  of a  previously  described  (15)  purification  protocol,  made 
possible by  the  recent  introduction  of resin-based,  pH-stable,  anion-exchange 
HPLC columns. The ability to load at a  pH (8.3) substantially above the pI of 
IL-1 (6.8) made it possible to achieve tight binding and thus eliminated the need 
to perform repetitive isocratic runs (15). The revised protocol also succeeded in 
using reverse-phase HPLC for the final step of the purification. Preparation of 
samples for sequence analysis by reverse-phase HPLC has been advocated (27) 
because of the high resolution provided by this technique and the purity and 
volatility of reverse-phase buffers. Our ability to use this technique for the final 
isolation of fully active IL-1  is mainly attributed to the introduction of columns 
specifically designed for labile protein separations (28). In addition, some of the 
difficulty originally encountered in using these columns as an initial purification 
step for IL-1 may have been due to the activation of acid hydrolases when crude 796  AMINO  ACID  SEQUENCE  OF  HUMAN  INTERLEUKIN  1 
supernatants  were exposed to  low-pH, reverse-phase  buffers (our unpublished 
observations). 
Progress  has  recently  been  made  in  defining  the  nucleic  acid  sequences of 
messenger RNA coding for IL-1.  Lomedico, et al. (12) have published a cloned 
cDNA coding for P388Dl-derived  murine  IL-1. This nucleotide sequence was 
validated by the sequencing of two peptides derived by CNBr cleavage of purified 
P388D1  IL-1.  Nevertheless,  the protein  encoded by this cDNA had very little 
homology with the amino acid sequence deduced from a  putative human  IL-1 
cDNA  recently  reported  by Auron,  et  al.  (18).  This  latter  cDNA  encoded  a 
protein which,  like IL-1, is active on the  D10.G4.1  T  cell line (19).  However, 
this  material  was  not  shown  to  be active  in  the  murine  thymocyte assay,  the 
standard assay for  IL-1, nor was the antiserum  used to immunoprecipitate  the 
translation products of this cDNA monospecific for human IL-1. It was therefore 
not possible to interpret  the significance of the differences beween the routine 
and human cDNA because the relationship of the human cDNA to human  IL-1 
protein was not established. 
The amino acid sequence data reported here demonstrates conclusively that 
the cDNA reported by Auron, et al. (18) does indeed code for human IL-1, and 
more specifically, for that species of human IL-1 having a pI of 6.8. The amino- 
terminal sequence analysis shows that the N-terminus of the secreted form of IL- 
l  begins  at  the  residue  Ala  (117)  encoded  by the  open  reading  frame.  The 
calculated molecular weight of the remaining polypeptide chain from Ala (117) 
to the end of the open reading frame (Ser [269]) is  17,380, in good agreement 
with the molecular weight obtained for our purified material  on homogeneous 
SDS-PAGE. This good correlation  between calculated and observed molecular 
weight is also consistent with the observation that no evidence for N-glycosylation 
was found at Ash (123) during  the amino-terminal  sequence analysis.  Previous 
studies (16,  29) of murine  and  human  IL-1  have suggested that  IL-1  is not a 
glycoprotein. The peptides I, II, and III correspond exactly with residues  137- 
151,247-263,  and 212-231  in the deduced sequence. One of these (peptide I) 
overlaps the N-terminal  sequence, and corroborates that analysis.  Furthermore, 
all of the peptide sequences follow methionines, as expected, since CNBr cleaves 
at methionine residues (21). The sequence of one of the peptides, II, is particu- 
larly important  because it lies within  five amino acids of the termination  of the 
open reading frame. This peptide shows that little or no processing of the human 
IL-1  translation  product occurs at the C-terminal  region of the molecule. This 
finding,  in  conjunction  with  the  identification  of the N-terminus  as Ala  (117) 
demonstrates that IL-1 is processed mainly or, perhaps, exclusively, at the amino- 
terminal end and not at the carboxy-terminal end, as was initially suspected (18). 
Interestingly, hydrophathicity plots (30) of the portion of the IL-1 molecule that 
lies 5'  of the secreted N-terminus show that  IL-1  does not have a  hydrophobic 
domain characteristic of a secretory leader or membrane anchor sequence. This 
species of IL-1 therefore is not likely to be responsible for the membrane-bound 
IL-1 activity that has been recently described (31). 
These findings  now make  it possible to compare  the translation  products of 
the cDNA reported for human and murine  IL-1, using the alignment provided 
by the amino-terminal  analysis reported  here.  The  specific bioactivities of the CAMERON  ET  AL.  797 
secreted  forms  of both  human  and  murine  IL-1  have  been  independently 
reported by ourselves (15) and Lomedico et al. (12) to be 1-2 x  10 ~ half-maximal 
U/mg in the murine thymocyte proliferation assay. Nevertheless, there is only 
29%  homology at the amino acid level between these secreted molecules, and 
only  30%  between the  complete translation  products.  This  striking  disparity 
between functional and  structural  relationships  raised the possibility that  the 
secondary structures of these two proteins may bring similar or identical amino 
acids into a  similar conformation on the surface of the molecule. Preliminary 
analysis of this type, however, using the Chou-Fasman algorithm (32) suggests 
that this is not the case (J. Boger and J. Schmidt, unpublished observations). At 
the nucleic acid level, 43%  homology was observed, suggesting that these two 
genes diverged from a  single parental gene and do not represent two genes of 
completely different  origin  converging  independently on  a  single  biological 
function. Such, for example, appears to be the case for egg white lysozyme and 
T4 lysozyme (32). 
Recent findings (26) suggest that the pI 6.8 species of human IL-1 is a member 
of a  closely related gene family. Van  Damme et al.  have reported the purifi- 
cation  and  amino-terminal  sequence  analysis  of  a  human  interferon-induc- 
ing factor. This material has the same N-terminal amino acid as human IL-1 (pI 
6.8), and comparison of the first 22 amino acids revealed 63% homology (Fig. 
5).  This  material  is  active  in  the  murine  thymocyte proliferation  assay,  but 
appears to have a specific bioactivity that is ~ 100-fold less than human or murine 
IL-1 (26). 
The  differences observed  between  the  pI  6.8  species  of human  IL-1  and 
murine IL-1, which has a pI of 4.9-5.2, raise questions concerning the biochem- 
ical composition of the low-pI species of human IL-1. The similar spectrum of 
biological  activities  shared  by  all  of the  charged species  of human  IL-1  has 
suggested that they might share similar core structures. However, the striking 
structural  differences between  the  mouse  and  human  IL-1,  despite  similar 
bioactivities, demonstrate that the different human IL-1  species need not have 
closely related structures.  One possibility,  suggested by the similar isoelectric 
points of mouse, pig, and certain of the human IL-1  species is that all of these 
will constitute a  family of related genes, largely distinct at the amino acid level 
from the  gene family represented by the pi-6.8  species of human  IL-1,  and 
interferon-inducing factor. Sequence analysis of these other human IL-1 species 
and cloning of their respective cDNA will clarify these issues. 
Summary 
The pi-6.8 species of normal human interleukin 1 (IL-1) has been isolated by 
ion-exchange and reverse-phase high-performance liquid chromatography. The 
isolated material had a molecular weight of 18,000, and had a specific bioactivity 
of 1.7  ×  107 half-maximal U/mg in the murine thymocyte proliferation assay, 
values  similar  to  those  obtained  for  murine  P388Dl-derived  IL-1  (12),  and 
human IL-1 isolated by a previously published purification protocol (15). Amino- 
terminal  sequence analysis  revealed a  single N-terminal,  and  resulted  in  the 
identification of 30 of the first 35 amino acid residues. Sequence of three CNBr 
cleavage fragments of purified IL-1 resulted in the identification of an additional 798  AMINO  ACID  SEQUENCE  OF  HUMAN  INTERLEUKIN  1 
lo  ~o 
HUMAN  I~  ~  Giu~Lys  ~-~Ala Ser Glu Met Met Ala Tyr ~  GlylAsn Glu Asp 
MURINE I~  Lys  ASp  Phe  GIu  Asp  Leu  Lys  Asn  Cys  GIu  Asn  Glu  As 
tO  20 
30  40 
ASp  Leu  Phe  Phe  Glu  kla  Asp  Gly  Pro  Lys  Gin  Met r~lCys~--e~elGInFs'PlLeu  Asp 
Tyr  Ser  Set  Ala  lie  Asp  HSs  Leu  Ser  Leu  Asn  G|n ~  -  ~r  Phe]TyrlAsp]Ala  Ser 
30  39 
Pro  .....  Gly  Gly  lie  Gin  Leu  Cys  lie  ASp  H~s 
~yr  Gly  Ser  His  Glu  Thr  Cys  Thr  Gin  Phe  Ve}  Ser  Thr  Glu  Thr 
49  59 
63  71 
H's  Tyr-  ~Lys  Gly-  ~Arg  Gin  AI.  AI8  Set ~-~  V.1  ~-  ~Met-- 
Set  Lys  Met  Asn  Phe  Thr  Lys  Glu  Set  -  Arg  Thr  Ser  Thr  Set 
69  78 
78  88 
-  -  Asp~  -  ~  Arg ~  Met  Leu  Val  Pro  Cys  Pro  Gin ~  Gin ~  Asn 
Ser  Asn  Gly  lie  Lys  Arg  Arg  Leu  Ser  Phe  Ser  Glu  Thr  Asp 
88  98 
98  108  ~  Ser  Thr  Phe  Phe  Pro  Phe  lie  Phe  Glu~ProIT~Phe  Ohe  Asp  Thr  Trp 
-  -  Gin  Ser  lie  Thr  His  Asp  Leu IGluGlullllelThr  Gin  Pro  Arg  - 
106  114 
"  118 
Interferoni~  Ala  Pro  Val  IGInEb..~  -  ~T_..~AsnlAlalThrl 
Inducing  ....  Ser  Ale  Pro  Thr  TyrlGIn  SerlAsplLeulArg  Tyr  Lys 
Factor  117  127 
135  140 
Phe  Thr  His  Lys  5er  Leu  Va%  Met  Glu  GIA 
Met  Lys  Leu  VaT  Arg  Gin  Lys  PhelVal  Met  Asn  Asp  Leu  Asn  Gin  Thr  lie  Tyr 
137  147 
GLULEULYS[ALALEUHIs-~---GLNGLYGlnASPMetGlu~]Gtn~~;~I.  - 
,.0  ,,.  ,.0  ,,.  L.u  .,~  ~  -  IG,o  ~,y  G,o  ,,p  ~_~J:~  -  ,,p 
Gin  Asp  Val  Asp  LySlMTSIT  r  Ser  Thr  Thr  Trp  Leu  AsnlAspJLeu  GIn lGInlGlulVall 
157  167 
166  17~ 
vo ,  sor  []  5or  vo ,  o , o  o, y  o, u  o , o  sor  ..o  -  ,  , .  .  , o 
Lys  ASp  Tyr  Ala  Tyr  Set  Set  Gly  Gly  -  Asp  Set  Tyr  Thr 
t77  186 
185  195 
~Gly  Leu  tys  Gfu  Lys  Asn~Tyr  Leu~Cys  Val  Leu  Lys  Asp~Lys~Thr 
LyS  lie  Ser  Asp  Set  Gin  Phe  Val  Ala  m  Gin  Gly  Glu  Gln  Val 
196  205 
204  214 
~Gln  Leu~-lSer  Val  Asp  -~Asn  Tyr  Pro  Lys  Lys  Lys  Met ~]LYS  ARG 
Leu  Lys  Leu  Pro  G1u  Thr  Leu  lie  Thr  -  -  Gly  Ser  Thr  Asp 
215  223 
224  234 
PHE  VAL [~ASN  LYS  ILE  GLU ~ASN~LEU  GLU~'~GLU~GIn  She[] 
Leu  Ile  Phe  Trp  kys Ser  Set  Ash  Tyr  Thr ISer  AlalA)a Tyr 
233  243 
Ash  Trp  TyrFl-~Ser[T-h-~Ser Gin  Ala  Ash  Met  PRO  PHE  GLY  GLY  THR  LYS 
Glu  Leu  Phe l]lellThrlAla  -  -  Lys  Gin  Ser  Arg  His  Ala krg  - 
251  259 
264 
FG~GLY  GLN  ASP  ILE  "HR  ASP  PH~THR-- Met  Gin  Phe  Val  Ser  Ser 
Leu  Pro  Ser  Met  ~hr  Asp  PheJ  Gin  Ile  Ser 
269 
FIGURE 5.  Comparison of amino acid sequences deduced fi'om cloned cDNA ~r human (18) 
and murine (12) IL-I. The numbers above and below the amino acid sequences are the residue 
numbers  ~r  the  complete human  and  murine  translation  products,  respectively. The  N- 
termini (*) of routine and human  I L-1,  as determined by sequence analysis of the purified, 
secreted proteins, are indicated. Those amino acids in human IL-1  that were confirmed in this 
report by sequence analysis of purified protein or peptide are capitalized. Also included is the 
N-terminal sequence of 22,000  tool wt inter~ron-inducing ~ctor, as described in  Ref. 26. 
Alignments were obtained using the Needleman-Wunsch homology algorithm (see Materials 
and Methods). Homologous amino acids are enclosed in boxes. CAMERON  ET  AL.  799 
38 residues. All of the sequences agree exactly with those deduced from comple- 
mentary  DNA  (cDNA)  by  Auron,  et  al.  (18),  demonstrating  that  this  cloned 
cDNA, though considerably different from the cDNA reported for murine IL-1 
(12), nevertheless codes for the pi-6.8 species of human IL-1. The evidence also 
shows that the precursor protein for human  IL-1  is largely processed at the N- 
terminal  end.  Little or  no  processing occurs at  the  carboxy-terminal end.  Se- 
quence homology with  interferon-inducing factor (26) suggests that the pi-6.8 
species of human IL-1 is a member ofa gene family. Although equally potent in 
the murine thymocyte proliferation assay, murine IL-1 and the pi-6.8 species of 
human  IL-1  are structurally distinct.  Further study will answer the interesting 
question as  to the relationship  of the  other charged species  of human  IL-1  to 
these distinct IL-1 classes. 
We thank  Drs.  P.  Davies,  I.  Sher, and  A.  Rosenthal  for encouragement and  support 
during the course of these experiments, and Drs. M. Tocci and J. Boger for many helpful 
suggestions and critical review of the manuscript. 
Received for publication  13 May 1985. 
Note added in proof: March et al. (Nature [Lond.]. 315:641) have reported the sequence 
ofa cDNA coding for a second human IL-1, which is 62% identical to murine IL-1 at the 
amino acid level. 
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